Aurobindo Pharma inks pact for respiratory products

25 Nov 2024 , 09:17 AM

Aurobindo Pharma announced on Saturday that its US-based business has signed a licensing arrangement with a global pharmaceutical company for the development of respiratory treatments. Aurobindo Pharma USA Inc has signed a collaboration and licensing agreement with a global pharmaceutical company to develop and commercialize pharmaceuticals, according to a regulatory filing.

The collaboration is expected to last three to five years in its initial phase of development.

According to the agreement, both parties would commercialise the products jointly and exclusively.

Aurobindo Pharma stated that once commercialised, the drugs will be manufactured at Partner’s facilities and marketed by both parties. 

Furthermore, both parties have agreed on a cost-sharing mechanism, with each contributing 50% of the costs incurred and Aurobindo receiving an aggregate cap of USD 90 Million for the development period, according to the statement.

According to the agreement, the unnamed multinational pharmaceutical business will own global manufacturing rights for the co-developed and commercialized pharmaceuticals.

Aurobindo Pharma said that the company has recorded an 8.6% YoY increase in Q2 net profit to ₹817 Crore for the second quarter of September 2024, driven by strong sales in Europe and growing regions. This was an increase over the ₹752 Crore net profit generated in the same quarter last year. However, on a quarterly (QoQ) basis, net profit fell 11%.

For feedback and suggestions, write to us at [e-mail]